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In this review, we describe cardiac manifestations in 62 APS. We will focus on the two major manifestations: 63 CVD and valvular disease. Major traditional and non-64 traditional risk factors for APS-associated atheroscle-65 rosis will be discussed followed by diagnostic and 66 therapeutic tools used during the management of CVD. 67 Other cardiac manifestations, such as valvular disease, 68 Libman-Sacks endocarditis, intracardiac thrombi and 69 myxomas, diastolic dysfunction and pulmonary hyper-70 tension, will also be briefly described (reviewed in 71 [1, [6] [7] [8] [9] [10] [11] [12] In 1993, it was suggested for the first time that APA 76 may be involved in atherosclerosis [13] . In this study, 77 possible cross-reactivity between APA and antioxidized 78 LDL (anti-oxLDL) antibody was also suggested [13] . mediators. There is an increased expression of cell and thus suppress T cell-driven autoimmunity [23] .
296
Statins also prevent endothelial dysfunction [49] . 
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301
Aspirin has been used for a long time to prevent CVD 302 and reduce mortality in the general population [23] . 303 Regarding APS, in a decision analysis model, aspirin 304 intake in 40-year-old lupus patients was estimated to 305 gain 3 months of quality-adjusted survival in APA 306 negative, and 11 months in APA positive individuals 307 [51] . APA positive SLE patients should be prescribed 308 aspirin if there are no contraindications [48, 50] . As 309 aspirin treatment has not been shown to add any benefit 310 over warfarin alone, the use of aspirin may not be 311 necessary in warfarin-treated patients [52] . Folic acid 312 and B vitamins may be used liberally [48] . Unfortu-313 nately, these data only suggest the potential benefit of 314 the use of such agents in APS, but there is no high-315 quality clinical evidence in this context.
316
Anti-inflammatory treatment utilized in APS may be 317 pro-or antiatherogenic [23, 36, 53] . Corticosteroids are 318 atherogenic by unfavorably affecting body fat distribu-319 tion, blood pressure and glucose metabolism leading to 320 dyslipidemia, hypertension and diabetes mellitus 321 [23, 36] . However, other studies were unable to confirm 322 an association between glucocorticoid use and athero-323 sclerosis [23, 36] . Controversy arises from the dual 324 action of glucocorticoids, as they are atherogenic, but, 325 on the other hand, also anti-inflammatory [23] . Thus, the 326 patients' own anti-inflammatory and metabolic response 327 to glucocorticoid therapy may influence the individual 328 therapeutic strategy to be used in a single APS patient 329 [2,3,23,36] (Table 1) .
330
In contrast to corticosteroids, antimalarial drugs, 331 such as chloroquine and HCQ, may exert evident 332 antiatherogenic properties [23] . In vitro studies suggest 333 that antimalarials may inhibit platelet aggregation and 334 the thrombogenic effects of APA [54, 55] . Despite these 335 potential benefits, the antiatherogenic effects of antima-336 larial drugs need to be clinically confirmed. 
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